BACKGROUND Levodopa is the mainstay of Parkinson's disease (PD) treatment, but is often eventually associated with disabling motor complications in patients with advanced PD. The inability of perorally administered levodopa to provide more physiologic continuous dopaminergic stimulation (CDS) is a leading hypothesis to explain these complications. OBJECTIVE To investigate the cumulative effic...

P a r k i n s o n ’s disease (PD) still has to be treated with dopaminergic drugs and levodopa is the most effective drug in the treatment of PD. Howe v e r, levodopa therapy presents two basic problems: its poor central availability (only about 1% of an oral levodopa dose reaches the brain) and its short elimination half-life (about one hour). Combination with a dopa-decarboxylase inhibitor (D...

OBJECTIVE To assess the effects of high frequency stimulation of the subthalamic nucleus (STN) on axial symptoms occurring in advanced stages of Parkinson's disease (PD). METHODS The efficacy of STN stimulation on total motor disability score (unified Parkinson's disease rating scale (UPDRS) part III) were evaluated in 10 patients with severe Parkinson's disease. The subscores were then studi...

Introdução. A rasagilina recentemente começou a ser utilizada no Brasil para tratar pacientes com Doença de Parkinson (DP) que apresentam complicações motoras consequentes ao uso da levodopa. Objetivo. Por um fármaco novo, o objetivo desta revisão sistemática foi avaliar os efeitos terapêuticos e segurança isoladamente associada levodopa tratamento dos sintomas motores DP. Método. As plataforma...

The authors previously showed that a single dose of levodopa improves the contrast sensitivity and decreases the size of fixation point scotomas in amblyopic patients. In the present study, they investigated the effect of levodopa after 1 wk of daily administration using a cross-over, double masked design. The decrease of fixation point scotomas was confirmed with automatic static perimetry. An...

Senek, M. 2018. New Approaches for Levodopa Treatment in Parkinson’s Disease. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1437. 84 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-0256-0. Parkinson’s disease (PD) is characterized by degeneration of dopaminergic cells, which results in dopamine depletion. Levodopa is the most effective sympto...

Coadministration of entacapone with levodopa attenuates motor complications in experimental models of Parkinson's disease. The mechanisms underlying entacapone effects are unknown. We investigated the effect of entacapone, on: long-duration response (LDR) to levodopa, levodopa-induced postsynaptic pharmacodynamic mechanisms and molecular changes in hemiparkinsonian rats. 6-Hydroxydopamine-unila...

Descrevemos um método eletroquímico para a determinação voltamétrica seqüencial de benserazida e levodopa usando cloroanil (CA) como eletro-catalisador. Para investigar a adequação do CA como mediador na oxidação eletrocatalitica da benserazida e levodopa, em solução aquosa, foram usadas a voltametria cíclica, voltametria de pulso diferencial, cronoamperometria e espectroscopia de impedância el...

Las distonías que responden a levodopa (DRD, siglas en inglés) abarcan un grupo de primarias, causadas por deficiencias enzimáticas la vía metabólica las aminas y, definición, comparten como característica principal su respuesta favorable y sostenida levodopa. Existen hasta seis genes asociados DRD, siendo el gen GCH1 más frecuentemente involucrado. La presentación típica esta entidad se caract...

A controlled release preparation of levodopa-carbidopa, CR III, given every 4 hours to 17 Parkinsonian patients for up to 10 months reduced plasma drug variations and improved motor response fluctuations compared with standard levodopa-carbidopa given every 2 hours. The results support the value of pharmaceutical approaches to the stabilisation of circulating levodopa levels in the treatment of...